Consumer Goods & Retail Global On demand · 24-48h

Global Baby Genetic Screening Market Strategic Research Report

Global Baby Genetic Screening Market Strategic Research Repo…

$3,500 USD

Strategic Research Report

Global Baby Genetic Screening Market

$8582025

5.3%CAGR

2032Forecast

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: NGS, Whole Exome Sequencing, Others

By Application: Public Hospitals, Private Hospitals, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific, Revvity, Quest Diagnostics, MedGenome, Mayo Clinic Laboratories, GeneDx, PreventionGenetics, SYNLAB, Veritas Genetics, ARCHIMEDlife, GGA, Cordlife, Rainbow Genomics, BGI Genomics, Berry Genomics, Annaroad, Jiajian Medical Testing, Genesky, Weihansi Biomedical Technology

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2025 · forecast to 2032

Length: 126 pages

Market size 2025

$858

Million USD

Forecast CAGR

5.3%

2025-2032

Forecast 2032

$1231.6

Projected

Regions

Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Baby Genetic Screening market size is predicted to grow from US$ 858 million in 2025 to US$ 1,224 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.

Baby Genetic Screening is a testing service offered for infants and young children to identify inherited or congenital conditions that may not be clinically obvious but could affect health and development if untreated. It typically uses a blood or cheek swab sample to screen for selected genetic disorders or risk markers, then provides results that guide confirmatory testing, medical follow-up, and early interventions when needed. Depending on the program, it may be positioned as an expanded option beyond standard newborn screening and is often accompanied by genetic counseling to help families understand findings and next steps.

Global key Baby Genetic Screening players cover Thermo Fisher Scientific, Revvity, Quest Diagnostics, MedGenome, Mayo Clinic Laboratories, etc.

This report presents a comprehensive overview of the global Baby Genetic Screening market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

NGS
Whole Exome Sequencing
Others

Segment by Screening Purpose

Core Condition Screening
Expanded Condition Screening

Segment by Application

Public Hospitals
Private Hospitals
Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Baby Genetic Screening market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Public Hospitals, Private Hospitals, Others evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Baby Genetic Screening Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports

Market size CAGR 5.3%

Regional growth momentum

Market share by segment

Key metrics

Base value

$858

2025

Forecast

$1231.6

2032

CAGR

5.3%

2025–2032

Regions

global

Key companies

Thermo Fisher ScientificRevvityQuest DiagnosticsMedGenomeMayo Clinic LaboratoriesGeneDxPreventionGeneticsSYNLAB

Segments covered in this report

By Type

NGSWhole Exome SequencingOthers

By Application

Public HospitalsPrivate HospitalsOthers

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 NGS
3.1.3 Whole Exome Sequencing
3.1.4 Others
3.1.5 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Public Hospitals
4.1.3 Private Hospitals
4.1.4 Others
4.1.5 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Thermo Fisher Scientific
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Revvity
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 Quest Diagnostics
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 MedGenome
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 Mayo Clinic Laboratories
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 GeneDx
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 PreventionGenetics
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 SYNLAB
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 Veritas Genetics
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 ARCHIMEDlife
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 GGA
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)
8.12 Cordlife
8.12.1 Company Overview
8.12.2 Key Products & Segments
8.12.3 Financial Performance (2023–2025)
8.12.4 Business Strategy
8.12.5 SWOT Analysis
8.12.6 Strategic Implications (2026–2032)
8.13 Rainbow Genomics
8.13.1 Company Overview
8.13.2 Key Products & Segments
8.13.3 Financial Performance (2023–2025)
8.13.4 Business Strategy
8.13.5 SWOT Analysis
8.13.6 Strategic Implications (2026–2032)
8.14 BGI Genomics
8.14.1 Company Overview
8.14.2 Key Products & Segments
8.14.3 Financial Performance (2023–2025)
8.14.4 Business Strategy
8.14.5 SWOT Analysis
8.14.6 Strategic Implications (2026–2032)
8.15 Berry Genomics
8.15.1 Company Overview
8.15.2 Key Products & Segments
8.15.3 Financial Performance (2023–2025)
8.15.4 Business Strategy
8.15.5 SWOT Analysis
8.15.6 Strategic Implications (2026–2032)
8.16 Annaroad
8.16.1 Company Overview
8.16.2 Key Products & Segments
8.16.3 Financial Performance (2023–2025)
8.16.4 Business Strategy
8.16.5 SWOT Analysis
8.16.6 Strategic Implications (2026–2032)
8.17 Jiajian Medical Testing
8.17.1 Company Overview
8.17.2 Key Products & Segments
8.17.3 Financial Performance (2023–2025)
8.17.4 Business Strategy
8.17.5 SWOT Analysis
8.17.6 Strategic Implications (2026–2032)
8.18 Genesky
8.18.1 Company Overview
8.18.2 Key Products & Segments
8.18.3 Financial Performance (2023–2025)
8.18.4 Business Strategy
8.18.5 SWOT Analysis
8.18.6 Strategic Implications (2026–2032)
8.19 Weihansi Biomedical Technology
8.19.1 Company Overview
8.19.2 Key Products & Segments
8.19.3 Financial Performance (2023–2025)
8.19.4 Business Strategy
8.19.5 SWOT Analysis
8.19.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Baby Genetic Screening market?

The global Baby Genetic Screening market is estimated at US$ 858 million in 2025 (base year) and is projected to reach US$ 1.22 billion by 2032.

What is the forecast CAGR for the Baby Genetic Screening market?

The market is expected to grow at a CAGR of 5.3% from 2026 to 2032, expanding from US$ 858 million in 2025 to US$ 1.22 billion in 2032, roughly 1.4 times its base-year value.

What is Baby Genetic Screening?

How is the Baby Genetic Screening market segmented by type?

By type, the market is segmented into NGS, Whole Exome Sequencing and Others.

What are the key applications of Baby Genetic Screening?

Key applications covered include Public Hospitals, Private Hospitals and Others.

Which companies are profiled in the Baby Genetic Screening market report?

Key players profiled include Thermo Fisher Scientific, Revvity, Quest Diagnostics, MedGenome, Mayo Clinic Laboratories, GeneDx, PreventionGenetics and SYNLAB, among 19 companies covered in total.

What geographies does the Baby Genetic Screening market analysis include?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

Who should buy the Baby Genetic Screening market report?

The report is intended for manufacturers and solution providers, distributors and end users in Public Hospitals, Private Hospitals and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Baby Genetic Screening market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.